Patents by Inventor Dorothea Starck

Dorothea Starck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of dopamine Dreceptor ligands for the production of drugs for treating renal function disorders
    Patent number: 8785447
    Abstract: The invention relates to the use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: July 22, 2014
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Bernd Mühlbauer, Gerhard Groβ, Dorothea Starck, Hans-Jörg Treiber
  • Triazole compounds and the therapeutic use thereof
    Patent number: 7465744
    Abstract: The invention relates to triazole compounds of general formula (I), wherein A, B, R1, R2, R3 and R4 have the meaning cited in claim 1. The invention also relates to a pharmaceutical agent containing at least one compound of general formula (I) in addition to the use of the compound (I) for producing a pharmaceutical agent for treating illnesses, responding to the effects of dopamine-D3-receptor antagonists or dopamine-D3-receptor agonists, especially for treating disorders in the central nervous system.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: December 16, 2008
    Assignee: Abbott GmbH & Co. KG
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Thomas Zierke, Georg Kettschau, Hervé Geneste, Andreas Haupt, Liliane Unger, Kai Blumbach, Dietmar Schöbel, Hans-Jurgen Teschendorf
  • Triazole compounds and the therapeutic use thereof
    Publication number: 20060241137
    Abstract: The invention relates to triazole compounds of general formula (I), wherein A, B, R1, R2, R3 and R4 have the meaning cited in claim 1. The invention also relates to a pharmaceutical agent containing at least one compound of general formula (I) in addition to the use of the compound (I) for producing a pharmaceutical agent for treating illnesses, responding to the effects of dopamine-D3-receptor antagonists or dopamine-D3-receptor agonists, especially for treating disorders in the central nervous system.
    Type: Application
    Filed: February 5, 2004
    Publication date: October 26, 2006
    Inventors: Dorothea Starck, Hans-Jurg Treiber, Thomas Zierke, Georg Kettschau, Hervé Geneste, Andreas Haupt, Lilliane Unger, Kai Blumbach, Dietmar Schöbel, Hans-Jurgen Teschendorf
  • USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS
    Publication number: 20060223793
    Abstract: The invention relates to the use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders.
    Type: Application
    Filed: June 16, 2006
    Publication date: October 5, 2006
    Inventors: Bernd Muhlbauer, Gerhard Gross, Dorothea Starck, Hans-Jorg Treiber
  • Dopamine Dreceptor ligands or antagonists for use in the treatment of renal function disorders
    Patent number: 7098214
    Abstract: Dopamine D3 receptor ligands or antagonists are disclosed for use in the treatment of renal function disorders, such as diabetic nephropathy.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: August 29, 2006
    Assignee: Abbott GmbH & Co. KG
    Inventors: Bernd Mühlbauer, Gerhard Gross, Dorothea Starck, Hans-Jörg Treiber
  • Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    Patent number: 6919342
    Abstract: The invention relates to triazole compounds of the general formula I wherein R1 is hydrogen or methyl, and R2 is C3-C4 alkyl or C1-C2 fluoroalkyl, as well as the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: July 19, 2005
    Assignee: Abbott GmbH & Co. KG
    Inventors: Andreas Haupt, Roland Grandel, Wilfried Braje, Hervé Geneste, Karla Drescher, Dorothea Starck, Hans-Jürgen Teschendorf
  • Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    Publication number: 20040259882
    Abstract: The invention relates to triazole compounds of the general formula I 1
    Type: Application
    Filed: June 4, 2004
    Publication date: December 23, 2004
    Inventors: Andreas Haupt, Roland Grandel, Wilfried Braje, Herve Geneste, Karla Drescher, Dorothea Starck, Hans-Jurgen Teschendorf
  • Triazole compounds with dopamine-D3-receptor affinity
    Patent number: 6602867
    Abstract: Triazole compounds of the following formula where R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: August 5, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • Triazole compounds with dopamine-D3-receptor affinity
    Patent number: 6583166
    Abstract: The invention relates to triazole compounds of formula (I), in which R1, R2, A and B have the meanings given in the description. The compounds provided for in the invention have a high affinity for the dopamine-D3-receptor and can therefore be used for the treatment of diseases which respond to the influence of dopamine-D3-ligands.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: June 24, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • Triazole compounds with dopamine-D3-receptor affinity
    Patent number: 6579892
    Abstract: Triazole compounds of the following formula where R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: June 17, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate
    Patent number: 6486162
    Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.
    Type: Grant
    Filed: January 8, 2002
    Date of Patent: November 26, 2002
    Assignee: Abbott Laboratories
    Inventors: Thomas Höger, Dorothea Starck, Hans-Jorg Treiber, Stefan Koser, Bernd Schaefer, Marco Thyes, Stefan Blank
  • Triazole compounds and the use thereof as dopamine-D3 -ligands
    Patent number: 6472392
    Abstract: Triazole compounds of the following formula: where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: October 29, 2002
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Stefan Blank, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Theophile-Marie Le Bris, Hans-Jürgen Teschendorf, Karsten Wicke
  • 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate
    Publication number: 20020143179
    Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.
    Type: Application
    Filed: January 8, 2002
    Publication date: October 3, 2002
    Inventors: Thomas Hoger, Dorothea Starck, Hans-Jorg Treiber, Bernd Schaefer, Stefan Koser, Marco Thyes, Stefan Blank
  • 3-Substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
    Patent number: 6414157
    Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: July 2, 2002
    Assignee: Abbott Laboratories
    Inventors: Wilfried Lubisch, Uta Dullweber, Dorothea Starck, Gerd Steiner, Alfred Bach, Franz Emling, Xavier Garcia-Ladona, Hans-Jürgen Teschendorf, Karsten Wicke
  • Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
    Patent number: 6387912
    Abstract: Use of pyrimidine derivatives of the formula I where the substituents are as defined in the description, and of their physiologically tolerated salts for producing medicaments for the prophylaxis and treatment of cerebral ischemia and strokes.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: May 14, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Gerd Steiner, Kurt Schellhaas, Wilfried Lubisch, Uta Holzenkamp, Dorothea Starck, Monika Knopp, Laszlo Szabo, Franz Emling, Francisco Javier Garcia-Ladona, Hans-Peter Hofmann, Liliane Unger
  • 3-substituted 3,4,5,7-tetrahedropyrrolo[3?,4?:4,5]thieno-[2,3-d]pyrimidine derivatives, their preparation and use
    Patent number: 6355647
    Abstract: 3-Substituted 3,4,5,7-tetrahydropyrrolo[3′,4′:4,5]thieno-[2,3-d]pyrimidine derivatives of the formula I in which the substituents have the meanings stated in the description, their preparation and their use as drugs.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: March 12, 2002
    Assignee: Abbott Laboratories
    Inventors: Gerd Steiner, Uta Dullweber, Dorothea Starck, Alfred Bach, Karsten Wicke, Hans-Jürgen Teschendorf, Francisco-Javier Garcia-Ladona, Franz Emling
  • Substituted AZA- and diazacycloheptane and -cyclooctane
    Patent number: 6352981
    Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula: Ar1—A—B—Ar2  (I) where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: March 5, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Hans-Jörg Treiber, Stefan Blank, Dorothea Starck, Liliane Unger, Hans-Jürgen Teschendorf, Karsten Wicke
  • 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-HT1A, 5HT1B and 5-HT1D)
    Patent number: 6346622
    Abstract: where the substituents have the meanings indicated in the description, their preparation and use as serotonin antagonists.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: February 12, 2002
    Assignee: Abbott Laboratories
    Inventors: Wilfried Lubisch, Uta Dullweber, Dorothea Starck, Gerd Steiner, Alfred Bach, Franz Emling, Xavier Garcia-Ladona, Hans-Jürgen Teschendorf, Karsten Wicke
  • 2{3-[4-(2-T-BUTYL-6-TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE
    Publication number: 20010020022
    Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.
    Type: Application
    Filed: February 10, 2000
    Publication date: September 6, 2001
    Inventors: STEFAN BLANK, DOROTHEA STARCK, HANS-JORG TREIBER, STEFAN KOSER, BERND SCHAFER, MARCO THYES, THOMAS HOGER
  • Substituted aza and diazacycloheptane and cyclooctane compounds and their use
    Patent number: 6214822
    Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula: Ar1—A—B—Ar2  (I) where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: April 10, 2001
    Assignee: BASF Aktiengesellschaft
    Inventors: Hans-Jörg Treiber, Stefan Blank, Dorothea Starck, Liliane Unger, Hans-Jürgen Teschendorf, Karsten Wicke